GRCE — Grace Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1444192 ·
Last close
$2.08
Market Cap
$33.85M
52W High
$2.71
52W Low
$1.85
ADV30
273,213
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,010,000 | -1,178,000 | 66,654,000 | 16,977,000 | 2,758,000 |
| Dec 2025 | 0 | — | -2,449,000 | -2,315,000 | 68,488,000 | 18,672,000 | 3,596,000 |
| Sep 2025 | 0 | — | -2,529,000 | -938,000 | 66,576,000 | 16,862,000 | 3,758,000 |
| Jun 2025 | 0 | — | -3,090,000 | -3,362,000 | 69,805,000 | 20,005,000 | 6,255,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,869,000
Investing CF
$0
Financing CF
$3,713,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.77
As of
2026-06-21
Balance + Analyst (yfinance extras)
Retained Earnings
$-228,480,000
Inventory
—
Receivables
$20,000
ST Investments
$15,000
EBIT TTM
$-11,078,000
Pretax Income TTM
$-9,493,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -11,077,000 | -7,793,000 | 66,654,000 | 2,758,000 | — | -8,869,000 |
| Mar 2025 | 0 | -16,679,000 | -9,568,000 | 71,993,000 | 5,383,000 | — | -14,904,000 |
| Mar 2024 | 0 | -11,367,000 | -12,853,000 | 73,300,000 | 11,557,000 | — | -12,333,000 |
| Mar 2023 | 0 | -18,247,000 | -42,429,000 | 79,123,000 | 11,168,000 | — | -15,913,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.55
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $2.08 · call oi: 2,733 · put oi: 128
Expected Move to 2026-11-20:
±$1.10
(52.88%) —
implied range
$0.98 –
$3.18
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BETRF | BetterLife Pharma Inc. | $33.75M | $0.21 | — |
| LTRN | Lantern Pharma Inc. | $33.56M | $2.63 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $33.28M | $0.79 | — |
| LITS | Lite Strategy, Inc. | $32.66M | $0.96 | — |
| IXHL | Incannex Healthcare Inc. | $35.18M | $2.94 | — |
News headlines (Yahoo Finance, 1h cache)
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
2026-07-28 11:00 · Yahoo
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
2026-06-18 12:00 · Yahoo
Sector Update: Health Care Stocks Edge Lower Late Afternoon
2026-04-23 19:51 · Yahoo
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
2026-04-23 17:13 · Yahoo
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
2026-04-14 12:00 · Yahoo
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate
2026-04-04 13:52 · Yahoo
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
2026-03-19 12:00 · Yahoo
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
2026-02-25 13:00 · Yahoo
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
2026-02-12 13:00 · Yahoo
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
2025-11-17 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.